Monitoring Duration After First Rituximab Dose in Pediatric Patients

Risk Profile for First Infusion

77% of pediatric patients experience reactions during the first infusion, with severe reactions occurring in approximately 10% of cases, according to the American Society of Clinical Oncology 1, 2
Fatal reactions have been documented, characterized by hypoxia, pulmonary infiltrates, respiratory distress, myocardial infarction, ventricular fibrillation, and cardiogenic shock, as reported by the American Academy of Pediatrics 2

The first dose should be administered at a slow initial rate, as recommended by the European Society for Medical Oncology 1, 3
Observation should continue for at least 1-2 hours after infusion completion, given the potential for delayed reactions and the severity profile of first-dose reactions, according to the American College of Clinical Pharmacy 2

All pediatric patients must receive premedication before the first dose, including antihistamine (e.g., diphenhydramine) and antipyretic (e.g., acetaminophen/paracetamol), as recommended by the American Academy of Pediatrics 1, 2

For Grade 1-2 reactions (mild to moderate), stop or slow the infusion rate immediately and provide symptomatic treatment, as recommended by the National Comprehensive Cancer Network 1, 2
For Grade 3-4 reactions (severe), stop the infusion immediately and administer aggressive symptomatic treatment, according to the American Heart Association 1, 2
Grade 4 reactions require permanent discontinuation, as recommended by the European Society for Medical Oncology 1